Ryan He Email & Phone Number

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques.

Provided executive program leadership for cross-functional development teams and drove the efficient advancement of high complexity global product development assets from product inception through commercialization of multiple indications in various therapeutic areas.- Led the global program team and drove the rapid advancement of brexanolone (SAGE-547), Sage’s first and most advanced pipeline asset: completed three Phase 3 studies for two indications (super refractory status epilepticus… Show more Provided executive program leadership for cross-functional development teams and drove the efficient advancement of high complexity global product development assets from product inception through commercialization of multiple indications in various therapeutic areas.- Led the global program team and drove the rapid advancement of brexanolone (SAGE-547), Sage’s first and most advanced pipeline asset: completed three Phase 3 studies for two indications (super refractory status epilepticus with orphan and fast track designation and postpartum depression with breakthrough therapy designation). Preparation for the postpartum depression (PPD) NDA filing is underway, and when approved, brexanolone would be the first approval of a transformative treatment for PPD with development timeline from start to finish in less than 3 years. Show less

Global Program Leader for ARISTADA and Program Director for Schizophrenia FranchisAlkermesLed the global program team and drove all aspects of product development of ARISTADA, long-acting injectable for treatment of schizophrenia, Alkermes’ only approved proprietary asset. Achieved first-in-human to NDA filing in less than 4 years. Additionally, as Program Director of Alkermes’ schizophrenia franchise, drove strategy development for ARISTADA launch readiness and lifecycle management… Show more Global Program Leader for ARISTADA and Program Director for Schizophrenia FranchisAlkermesLed the global program team and drove all aspects of product development of ARISTADA, long-acting injectable for treatment of schizophrenia, Alkermes’ only approved proprietary asset. Achieved first-in-human to NDA filing in less than 4 years. Additionally, as Program Director of Alkermes’ schizophrenia franchise, drove strategy development for ARISTADA launch readiness and lifecycle management (LCM) as well as new product planning for ALKS 3831, a novel oral antipsychotic for schizophrenia with a favorable weight and metabolic profile. Show less